Nuvectis Pharma, Inc. – NASDAQ:NVCT

Nuvectis Pharma stock price today

$6.14
+0.91
+17.62%
Financial Health
0
1
2
3
4
5
6
7
8
9

Nuvectis Pharma stock price monthly change

-20.67%
month

Nuvectis Pharma stock price quarterly change

-20.67%
quarter

Nuvectis Pharma stock price yearly change

-37.78%
year

Nuvectis Pharma key metrics

Market Cap
88.72M
Enterprise value
N/A
P/E
-9.45
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
12.53
PEG ratio
0.24
EPS
-1.38
Revenue
N/A
EBITDA
-23.19M
Income
-22.38M
Revenue Q/Q
-100%
Revenue Y/Y
-196.49%
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Nuvectis Pharma stock price history

Nuvectis Pharma stock forecast

Nuvectis Pharma financial statements

Nuvectis Pharma, Inc. (NASDAQ:NVCT): Profit margin
Jun 2023 0 -5.70M
Sep 2023 0 -5.88M
Dec 2023 -4.10M -6.62M 161.47%
Mar 2024 0 -4.17M
Nuvectis Pharma, Inc. (NASDAQ:NVCT): Analyst Estimates
2025 23.06M -29.10M -126.18%
2026 1.97M -33.51M -1700.81%
2027 31.45M -6.94M -22.09%
2028 75.11M 12.28M 16.36%
  • Analysts Price target

  • Financials & Ratios estimates

Nuvectis Pharma, Inc. (NASDAQ:NVCT): Earnings per share (EPS)
2024-03-05 -0.4 -0.41
2024-05-07 -0.4 -0.25
Nuvectis Pharma, Inc. (NASDAQ:NVCT): Debt to assets
Jun 2023 24941000 4.60M 18.48%
Sep 2023 22262000 5.57M 25.05%
Dec 2023 19185000 6.98M 36.4%
Mar 2024 19714000 5.69M 28.87%
Nuvectis Pharma, Inc. (NASDAQ:NVCT): Cash Flow
Jun 2023 -4.08M 0 13.21M
Sep 2023 -3.24M 0 703K
Dec 2023 -3.85M 0 917K
Mar 2024 -4.35M 0 4.69M

Nuvectis Pharma alternative data

Nuvectis Pharma, Inc. (NASDAQ:NVCT): Employee count
Aug 2023 11
Sep 2023 11
Oct 2023 11
Nov 2023 11
Dec 2023 11
Jan 2024 11
Feb 2024 11
Mar 2024 13
Apr 2024 13
May 2024 13
Jun 2024 13
Jul 2024 13

Nuvectis Pharma other data

1.44% -5.56%
of NVCT is owned by hedge funds
182.36K -801.56K
shares is hold by hedge funds

Nuvectis Pharma, Inc. (NASDAQ:NVCT): Insider trades (number of shares)
Period Buy Sel
May 2024 5553 0
Nov 2024 22000 2755
Dec 2024 34000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
MOSSERI MARLIO CHARLES 10 percent owner
Common Stock 17,000 $4.7 $79,900
Purchase
MOSSERI MARLIO CHARLES 10 percent owner
Common Stock 17,000 $4.7 $79,900
Purchase
PORADOSU ENRIQUE officer: Chief Science & Busine..
Common Stock 2,000 $4.99 $9,980
Purchase
BENTSUR RON director, 10 percent owner, off..
Common Stock 20,000 $4.92 $98,400
Sale
CARSON MICHAEL J. officer: Vice President, Finance
Common Stock 2,755 $8.16 $22,478
Purchase
BENTSUR RON director, 10 percent owner, off..
Common Stock 1,940 $6.74 $13,076
Purchase
PORADOSU ENRIQUE officer: Chief Science & Busine..
Common Stock 500 $6.29 $3,145
Purchase
SHEMESH SHAY officer: Chief Dev. & Ops. Offi..
Common Stock 1,113 $6.32 $7,034
Purchase
BENTSUR RON director, 10 percent owner, off..
Common Stock 2,000 $6.4 $12,800
Purchase
BENTSUR RON director, 10 percent owner, off..
Common Stock 640 $11.08 $7,091
Monday, 25 November 2024
zacks.com
Thursday, 14 November 2024
benzinga.com
Wednesday, 13 November 2024
zacks.com
Thursday, 7 November 2024
zacks.com
Tuesday, 5 November 2024
globenewswire.com
Monday, 28 October 2024
businesswire.com
Thursday, 29 August 2024
globenewswire.com
Tuesday, 6 August 2024
globenewswire.com
Tuesday, 28 May 2024
investorplace.com
Friday, 24 May 2024
zacks.com
Thursday, 16 May 2024
globenewswire.com
Tuesday, 7 May 2024
globenewswire.com
Monday, 8 April 2024
globenewswire.com
Tuesday, 2 April 2024
InvestorPlace
Friday, 15 March 2024
GlobeNewsWire
Friday, 9 February 2024
GlobeNewsWire
GlobeNewsWire
Wednesday, 3 January 2024
GlobeNewsWire
Monday, 16 October 2023
Zacks Investment Research
Monday, 25 September 2023
GlobeNewsWire
Wednesday, 6 September 2023
Seeking Alpha
Friday, 1 September 2023
GlobeNewsWire
Monday, 10 July 2023
Zacks Investment Research
Monday, 5 June 2023
Zacks Investment Research
Wednesday, 31 May 2023
Zacks Investment Research
Monday, 15 May 2023
Zacks Investment Research
Thursday, 27 April 2023
GlobeNewsWire
Wednesday, 16 November 2022
24/7 Wall Street
Monday, 3 October 2022
GlobeNewsWire
Wednesday, 7 September 2022
GlobeNewsWire
  • What's the price of Nuvectis Pharma stock today?

    One share of Nuvectis Pharma stock can currently be purchased for approximately $6.14.

  • When is Nuvectis Pharma's next earnings date?

    Unfortunately, Nuvectis Pharma's (NVCT) next earnings date is currently unknown.

  • Does Nuvectis Pharma pay dividends?

    No, Nuvectis Pharma does not pay dividends.

  • How much money does Nuvectis Pharma make?

    Nuvectis Pharma has a market capitalization of 88.72M. Nuvectis Pharma made a loss 22.26M US dollars in net income (profit) last year or -$0.25 on an earnings per share basis.

  • What is Nuvectis Pharma's stock symbol?

    Nuvectis Pharma, Inc. is traded on the NASDAQ under the ticker symbol "NVCT".

  • What is Nuvectis Pharma's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Nuvectis Pharma?

    Shares of Nuvectis Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Nuvectis Pharma have?

    As Jul 2024, Nuvectis Pharma employs 13 workers.

  • When Nuvectis Pharma went public?

    Nuvectis Pharma, Inc. is publicly traded company for more then 3 years since IPO on 4 Feb 2022.

  • What is Nuvectis Pharma's official website?

    The official website for Nuvectis Pharma is nuvectis.com.

  • Where are Nuvectis Pharma's headquarters?

    Nuvectis Pharma is headquartered at 1 Bridge Plaza, Fort Lee, NJ.

  • How can i contact Nuvectis Pharma?

    Nuvectis Pharma's mailing address is 1 Bridge Plaza, Fort Lee, NJ and company can be reached via phone at +20 16143150.

Nuvectis Pharma company profile:

Nuvectis Pharma, Inc.

nuvectis.com
Exchange:

NASDAQ

Full time employees:

13

Industry:

Biotechnology

Sector:

Healthcare

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

1 Bridge Plaza
Fort Lee, NJ 07024

CIK: 0001875558
ISIN: US67080T1088
CUSIP: 67080T108